Content’s Industrial Revolution: Shaping the Future of Pharma
by Turacoz | Medical Publishing, Medical Writing
Communications
In a rapidly evolving digital ecosystem, the pharmaceutical
industry’s relationship with content is undergoing a seismic shift. At the
recent Reuters Pharma event in Barcelona, Dr.
Namrata, Founder of Turacoz, led a thought-provoking panel discussion
titled ‘Content’s Industrial Revolution’. The dialogue explored how
content in pharma is undergoing a transformation driven by technology,
collaboration, and an evolving mindset.
This transformation isn’t just about producing more content
– it’s about producing smarter content that is personalized,
compliant, and delivered at speed and scale. Here are the key takeaways that
highlight how pharma companies can adapt to this revolution.
From linear to circular: Rethinking the content supply
chain
Traditionally, the content supply chain in pharma has been
linear – ideation, creation, review, and deployment. But the industry is waking
up to a powerful realization: a circular content supply chain is the
way forward. This means insights from content consumption must loop back
into content creation.
It’s about listening, learning, and evolving continuously.
When feedback and performance metrics inform the next content iteration, the
result is more relevant, targeted, and effective communication.
Upfront partnerships: Shifting left in the review process
Another game-changing approach discussed in the panel was
the concept of “shifting left” – engaging reviewers early in the
content lifecycle. Instead of waiting until the end of the process for
medical, legal, and regulatory (MLR) reviews, involving them upfront leads to
fewer iterations and a higher rate of getting content right the first
time. “Involving reviewers early and leveraging AI is no longer
optional—it’s the only way to create content that’s both fast and flawless,” noted
Dr. Namrata during the panel. This proactive alignment improves efficiency,
saves time, and ensures clarity from the start.
AI and GenAI in Action: Smarter, Faster, Compliant
Nearly 80% of pharma companies are now
embedding AI into their content workflows.1 The
path forward lies in industrialization—standardizing content processes to
eliminate duplication and reduce costs. This includes:
- Tiered
review systems based on content similarity
- Modular
content structures for reuse and recycling
- AI-led
automation for reference linking and claims validation
These innovations reduce manual effort and error,
speed up reviews and improve compliance and traceability.
Reduce, reuse, recycle: Sustainable content practices
Content sustainability is now a business imperative.
Strategies like modular content creation, centralized digital libraries, and
approved content recycling help reduce production time and content
fatigue—while ensuring consistency across global teams.
Let’s break down what reduce, reuse, and recycle means
in the pharma content world:
- Reduce
Minimize duplication by avoiding the creation of redundant content. Use centralized libraries and templates to streamline creation and approval processes. - Reuse
Build modular content blocks that can be repurposed across different channels, regions, and campaigns. One approved module (e.g., a product description) can be reused in emails, websites, and brochures. - Recycle
Refresh and repackage existing high-performing content instead of always starting from scratch. This ensures content stays relevant and reduces production time.
These sustainable practices improve efficiency, maintain
global consistency, and cut down costs.
Mindset, toolset, and skillset: The three pillars of
change
Technology is only part of the equation. To truly embrace
this revolution, organizations need the right:
- Mindset: Be
curious, open to learning, and willing to fail fast
- Toolset: Adopt
tech that enables agility without sacrificing compliance
- Skillset: Invest
in training and upskilling teams for the future of content
Internal and external collaboration will be the glue that
holds these pillars together ensuring that strategy, execution, and innovation
move in sync.
Human + Machine: A balanced equation
While technology is a powerful enabler, the human
touch remains irreplaceable. Keeping humans in the loop ensures contextual
accuracy, emotional intelligence, and ethical responsibility especially
critical in healthcare communications. The goal is to strike the right balance
between automation and human oversight.
Final thoughts
As the content landscape shifts from volume to value, pharma
companies need to focus on crafting impactful content that resonates with the
audience. This means not just doing things faster but doing them better –
with clarity, compliance, and compassion.
At Turacoz, we are proud to be at the forefront of this
transformation, driving change that empowers our clients to communicate with
precision and purpose. The content revolution is here—and we’re ready to lead
it.
Ready to transform your content strategy? Connect with
Turacoz to explore how we can help you scale smarter.
Reference:
Kudumala A, Konersmann T, Israel A, Miranda W. Biopharma
digital transformation: Gain an edge with leapfrog digital innovation. Deloitte
Insights. 2021 Dec 8. Available from: https://www2.deloitte.com/us/en/insights/industry/life-sciences/biopharma-digital-transformation.html
We’re social